Amylyx Pharmaceuticals Files 8-K
Ticker: AMLX · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1658551
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Amylyx filed an 8-K, likely a routine update, check for details.
AI Summary
Amylyx Pharmaceuticals, Inc. filed an 8-K on March 8, 2024, to report on other events and potentially financial statements and exhibits. The filing does not detail specific events or financial figures but serves as a notification to the SEC.
Why It Matters
This filing indicates Amylyx Pharmaceuticals is making a regulatory disclosure to the SEC, which could pertain to significant corporate events or financial updates.
Risk Assessment
Risk Level: low — The filing is a standard 8-K notification without specific negative or positive disclosures, making the immediate risk level low.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- 001-41199 (company) — SEC File Number
- 46-4600503 (company) — IRS Employer Identification No.
- March 8, 2024 (date) — Date of Report
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits' as item information, but does not provide specific details within the provided text.
When was this 8-K filed?
This 8-K was filed on March 8, 2024.
What is the exact name of the company filing the report?
The exact name of the registrant is Amylyx Pharmaceuticals, Inc.
What is the company's principal executive office address?
The address of the principal executive offices is 43 Thorndike St., Cambridge, MA 02141.
What is the company's telephone number?
The registrant's telephone number, including area code, is (617) 682-0917.
Filing Stats: 1,120 words · 4 min read · ~4 pages · Grade level 13.3 · Accepted 2024-03-08 07:10:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
Filing Documents
- d787565d8k.htm (8-K) — 31KB
- d787565dex991.htm (EX-99.1) — 30KB
- 0001193125-24-062878.txt ( ) — 190KB
- amlx-20240308.xsd (EX-101.SCH) — 3KB
- amlx-20240308_lab.xml (EX-101.LAB) — 17KB
- amlx-20240308_pre.xml (EX-101.PRE) — 11KB
- d787565d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements contained in this Form 8-K and related comments in our conference call speak only as of the date on which they were made.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release of the Company, dated March 8, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: March 8, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer